Cargando…
Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population
C-peptide measurement may represent a better index of pancreatic β-cell function compared to insulin. While insulin is mainly cleared by liver, C-peptide is mainly metabolized by kidneys. The aim of our study was to evaluate the association between baseline plasma C-peptide level and the development...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564789/ https://www.ncbi.nlm.nih.gov/pubmed/32957570 http://dx.doi.org/10.3390/jcm9093001 |
_version_ | 1783595794258984960 |
---|---|
author | Sokooti, Sara Kieneker, Lyanne M. de Borst, Martin H. Muller Kobold, Anneke Kootstra-Ros, Jenny E. Gloerich, Jolein van Gool, Alain J. Heerspink, Hiddo J. Lambers T Gansevoort, Ron Dullaart, Robin P.F. Bakker, Stephan J. L. |
author_facet | Sokooti, Sara Kieneker, Lyanne M. de Borst, Martin H. Muller Kobold, Anneke Kootstra-Ros, Jenny E. Gloerich, Jolein van Gool, Alain J. Heerspink, Hiddo J. Lambers T Gansevoort, Ron Dullaart, Robin P.F. Bakker, Stephan J. L. |
author_sort | Sokooti, Sara |
collection | PubMed |
description | C-peptide measurement may represent a better index of pancreatic β-cell function compared to insulin. While insulin is mainly cleared by liver, C-peptide is mainly metabolized by kidneys. The aim of our study was to evaluate the association between baseline plasma C-peptide level and the development of type 2 diabetes independent of glucose and insulin levels and to examine potential effect-modification by variables related to kidney function. We included 5176 subjects of the Prevention of Renal and Vascular End-Stage Disease study without type 2 diabetes at baseline. C-peptide was measured in plasma with an electrochemiluminescent immunoassay. Cox proportional hazards regression was used to evaluate the association between C-peptide level and type 2 diabetes development. Median C-peptide was 722 (566–935) pmol/L. During a median follow-up of 7.2 (6.0–7.7) years, 289 individuals developed type 2 diabetes. In multivariable-adjusted Cox regression models, we observed a significant positive association of C-peptide with the risk of type 2 diabetes independent of glucose and insulin levels (hazard ratio (HR): 2.35; 95% confidence interval (CI): 1.49–3.70). Moreover, we found significant effect modification by hypertension and albuminuria (p < 0.001 and p = 0.001 for interaction, respectively), with a stronger association in normotensive and normo-albuminuric subjects and absence of an association in subjects with hypertension or albuminuria. In this population-based cohort, elevated C-peptide levels are associated with an increased risk of type 2 diabetes independent of glucose, insulin levels, and clinical risk factors. Elevated C-peptide level was not independently associated with an increased risk of type 2 diabetes in individuals with hypertension or albuminuria. |
format | Online Article Text |
id | pubmed-7564789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75647892020-10-26 Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population Sokooti, Sara Kieneker, Lyanne M. de Borst, Martin H. Muller Kobold, Anneke Kootstra-Ros, Jenny E. Gloerich, Jolein van Gool, Alain J. Heerspink, Hiddo J. Lambers T Gansevoort, Ron Dullaart, Robin P.F. Bakker, Stephan J. L. J Clin Med Article C-peptide measurement may represent a better index of pancreatic β-cell function compared to insulin. While insulin is mainly cleared by liver, C-peptide is mainly metabolized by kidneys. The aim of our study was to evaluate the association between baseline plasma C-peptide level and the development of type 2 diabetes independent of glucose and insulin levels and to examine potential effect-modification by variables related to kidney function. We included 5176 subjects of the Prevention of Renal and Vascular End-Stage Disease study without type 2 diabetes at baseline. C-peptide was measured in plasma with an electrochemiluminescent immunoassay. Cox proportional hazards regression was used to evaluate the association between C-peptide level and type 2 diabetes development. Median C-peptide was 722 (566–935) pmol/L. During a median follow-up of 7.2 (6.0–7.7) years, 289 individuals developed type 2 diabetes. In multivariable-adjusted Cox regression models, we observed a significant positive association of C-peptide with the risk of type 2 diabetes independent of glucose and insulin levels (hazard ratio (HR): 2.35; 95% confidence interval (CI): 1.49–3.70). Moreover, we found significant effect modification by hypertension and albuminuria (p < 0.001 and p = 0.001 for interaction, respectively), with a stronger association in normotensive and normo-albuminuric subjects and absence of an association in subjects with hypertension or albuminuria. In this population-based cohort, elevated C-peptide levels are associated with an increased risk of type 2 diabetes independent of glucose, insulin levels, and clinical risk factors. Elevated C-peptide level was not independently associated with an increased risk of type 2 diabetes in individuals with hypertension or albuminuria. MDPI 2020-09-17 /pmc/articles/PMC7564789/ /pubmed/32957570 http://dx.doi.org/10.3390/jcm9093001 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sokooti, Sara Kieneker, Lyanne M. de Borst, Martin H. Muller Kobold, Anneke Kootstra-Ros, Jenny E. Gloerich, Jolein van Gool, Alain J. Heerspink, Hiddo J. Lambers T Gansevoort, Ron Dullaart, Robin P.F. Bakker, Stephan J. L. Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population |
title | Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population |
title_full | Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population |
title_fullStr | Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population |
title_full_unstemmed | Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population |
title_short | Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population |
title_sort | plasma c-peptide and risk of developing type 2 diabetes in the general population |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564789/ https://www.ncbi.nlm.nih.gov/pubmed/32957570 http://dx.doi.org/10.3390/jcm9093001 |
work_keys_str_mv | AT sokootisara plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT kienekerlyannem plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT deborstmartinh plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT mullerkoboldanneke plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT kootstrarosjennye plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT gloerichjolein plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT vangoolalainj plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT heerspinkhiddojlambers plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT tgansevoortron plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT dullaartrobinpf plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation AT bakkerstephanjl plasmacpeptideandriskofdevelopingtype2diabetesinthegeneralpopulation |